PercuSurge GuardWire Associated With Fewer Adverse Cardiac Events
This article was originally published in The Gray Sheet
Executive Summary
A comparatively low rate of major adverse cardiac events (MACE) in patients treated with Medtronic/PercuSurge's GuardWire distal protection device during saphenous vein graft repair procedures contributed to a favorable FDA panel review, despite concerns about the device's malfunction rate.
You may also be interested in...
Drug-Coated Stents, Distal Protection Devices: DCRD Explicates DMC Benefits
Device firms employing data monitoring committees to evaluate clinical trials should ensure that DMCs operate under a clearly defined protocol, according to CDRH's Division of Cardiovascular & Respiratory Devices
Drug-Coated Stents, Distal Protection Devices: DCRD Explicates DMC Benefits
Device firms employing data monitoring committees to evaluate clinical trials should ensure that DMCs operate under a clearly defined protocol, according to CDRH's Division of Cardiovascular & Respiratory Devices
Medtronic GuardWire Begins Controlled Roll-Out In U.S. Market
Medtronic PercuSurge is planning to submit an IDE application in the next two months for a 500-600 patient trial evaluating its GuardWire distal protection device in patients with acute myocardial infarction.